Merck tops third-quarter forecasts on strong Keytruda and Gardasil results

Sales for Merck's pulmonary-hypertension treatment Winrevair continue to surge, up 93% year over year to $694 million in the third quarter. The drug's growth was fueled by higher demand as well as strong wholesaler and specialty pharmacy purchasing patterns in the U.S., the company says. It also po…